Compare DLO & ARQT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DLO | ARQT |
|---|---|---|
| Founded | 2013 | 2016 |
| Country | Uruguay | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.4B | 3.3B |
| IPO Year | 2021 | 2020 |
| Metric | DLO | ARQT |
|---|---|---|
| Price | $12.86 | $23.69 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 6 |
| Target Price | $17.25 | ★ $34.00 |
| AVG Volume (30 Days) | ★ 1.7M | 1.1M |
| Earning Date | 05-14-2026 | 05-05-2026 |
| Dividend Yield | ★ 1.56% | N/A |
| EPS Growth | N/A | ★ 88.79 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $376,072,000.00 |
| Revenue This Year | $26.65 | $34.46 |
| Revenue Next Year | $24.48 | $29.77 |
| P/E Ratio | $22.27 | ★ N/A |
| Revenue Growth | N/A | ★ 91.34 |
| 52 Week Low | $7.61 | $11.86 |
| 52 Week High | $16.78 | $31.77 |
| Indicator | DLO | ARQT |
|---|---|---|
| Relative Strength Index (RSI) | 54.55 | 50.47 |
| Support Level | $11.67 | $22.56 |
| Resistance Level | $13.50 | $27.26 |
| Average True Range (ATR) | 0.66 | 0.95 |
| MACD | 0.11 | 0.28 |
| Stochastic Oscillator | 72.86 | 74.71 |
DLocal Ltd is focused on making the complex simple, redefining the online payment experience in emerging markets. Through its technology platform, One dLocal, the company enables world-wide enterprise merchants to get paid (pay-in) and to make payments (pay-out) online in a safe and efficient manner. The company earns revenue from fees charged to merchants in connection with payment processing services for cross-border and local payment transactions. The company's geographical segments include Latin America and Non-Latin America with a majority of its revenue being generated from Brazil in Latin America region.
Arcutis Biotherapeutics Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for dermatological diseases with high unmet medical needs. Its current portfolio is comprised of differentiated topical and systemic treatments with potential to treat immune-mediated dermatological diseases and conditions. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population. The Company has one reportable segment relating to the development and commercialization of treatments for dermatological diseases.